

www.eano.eu



© 2019 by Christian Stemper

17TH MEETING & EDUCATIONAL DAY
OF THE EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY

EANO 2022

VIENNA, AUSTRIA

PROGRAMME

SEPT 15-18, 2022

HOFBURG VIENNA





www.eano.eu

EANO

**EUROPEAN ASSOCIATION
OF NEURO-ONCOLOGY**



#btsm

EANO, founded in 1994, is Europe's multidisciplinary Neuro-Oncology organisation representing all medical and scientific disciplines involved in the prevention, diagnosis and treatment of tumours of the central nervous system (CNS).

The EANO mission is:

- ✓ To provide vital resources for your career including educational seminars, cutting-edge news and research reports/items;
- ✓ To enhance collaboration between all relevant disciplines to facilitate bridging science, knowledge and practice gaps in the management of CNS malignancies;
- ✓ To support the entire speciality of neuro-oncology through political advocacy, patient and public outreach;
- ✓ To accelerate standards of care by developing guidelines;
- ✓ To enable free access to the journals Neuro-Oncology and Neuro-Oncology Practice, as well as to the Neuro-Oncology Advances;
- ✓ To offer reduced registration fees for EANO Meetings and special teaching events;
- ✓ To encourage all members to apply for scholarships and awards.

**Learn more
about an EANO
membership on
www.eano.eu**

**We are looking forward
to meeting you!**

neurologists
neuropsychologists
laboratory scientists
palliative care specialists
radiologists

MEDICAL PROFESSIONALS

NURSES



ALLIED HEALTH PROFESSIONALS

SCIENTISTS

NEXT GENERATION

pediatric neuro-oncologists
allied health professionals
neurosurgeons

**EANO UNITES ON A MULTINATIONAL AND MULTIDISCIPLINARY LEVEL
NEURO-ONCOLOGY EXPERTS ACROSS BORDERS**

WELCOME

Dear EANO members, friends, and colleagues,



I am delighted to welcome you in Vienna for the 17th EANO Annual Meeting taking place from September 15th - 18th, 2022.

The programme of the educational day and the main meeting will highlight the most recent findings in basic, translational, and clinical science from all fields of Neuro-Oncology and provides a superb platform for discussion of the most recent data. Whether you are a clinician, a scientist, a nurse specialized in Neuro-Oncology or new in the field, you will find presentations that will increase your knowledge. The speakers come from many countries, institutions and specialties and will give you a plethora of information and experiences that will make the EANO 2022 another successful meeting.

We are very happy and proud to have received more than 370 submissions of original contributions that will be shared in oral and poster presentations and will surely lead to lively exchange and generate new cooperations and research ideas.

I thank the EANO Meeting Office, the EANO Committees, my team members and all supporters for the dedicated work and collaboration in organising the conference! Let's enjoy together the exciting scientific exchange, the strengthening of collaborations and friendships, and, if our busy congress schedules allow, also the wide range of cultural and culinary pleasures the beautiful city of Vienna has to offer!

Welcome to Vienna and the EANO Meeting 2022!

A handwritten signature in blue ink, appearing to read 'Matthias Preusser', with a stylized, flowing script.

Matthias Preusser
President EANO & EANO Meeting 2022

EANO Executive Board

President: Matthias Preusser, Austria

Past President: Martin van den Bent, Netherlands

Treasurer: Roberta Rudà, Italy

Members:

Anthony Chalmers, United Kingdom

Asgeir Jakola, Sweden

Simone Niclou, Luxembourg

Karin Piil, Denmark

Patrick Roth, Switzerland

Felix Sahm, Germany

Marilena Theodorou, Cyprus

EANO Scientific Committee

Chair: Michael Platten, Germany

Co-Chair: Manuel Valiente, Spain

Members:

Antonella Castellano, Italy

Asgeir Jakola, Sweden

Benedikt Hasselbalch, Denmark

Christian Mawrin, Germany

Elizabeth Cohen-Jonathan Moyal, France

Federico Pessina, Italy

Florien Willemijn Boele, United Kingdom

Jan-Michael Werner, Germany
(Youngsters Representative)

Matthias Preusser, Austria

Oliver Hanemann, United Kingdom

Pim French, Netherlands

Tareq Juratli, Germany

EANO Congress Organiser

European Association of
Neuro-Oncology c/o WMA GmbH
Alser Strasse 4
1090 Vienna, Austria

Congress President:

Matthias Preusser, Austria

Scientific Management,
Exhibition and Sponsorship,
General organisation and logistics
WMA GmbH
Lydia Schnedl

Julian Piskula

T: +43 1 4051383-14

E: eano-meetings@eano.eu

W: www.eano.eu/eano2022

EANO Office

Alissa McGregor
c/o WMA GmbH
Alser Strasse 4
1090 Vienna, Austria
T: +43 1 4051383-41
E: office@eano.eu
W: www.eano.eu



www.eano.eu

EANO

EUROPEAN ASSOCIATION
OF NEURO-ONCOLOGY

THURSDAY SEPTEMBER 15, EDUCATIONAL DAY

	Educational Day Basic Science track	Educational Day Clinical track	Educational Day Nurses/AHPs track
	ZEREMONIENSAAL Mezzanine	FORUM Ground Floor	KÜNSTLERZIMMER Mezzanine
08.55 - 10.00	EDB01 Importance of Interdisciplinary in Neuro-Oncology	EDC01 Epilepsy in Neuro-Oncology	EDN01 Symptom science
10.00 - 10.10	TIME TO CHANGE ROOMS		
10.10 - 11.30	EDB02 Immunology and Immunotherapies	EDC02 Hot topics	EDN02 Person-centered health care in neuro-oncology
11.30 - 12.00	COFFEE BREAK		
12.00 - 13.15	EDB03 Technological advances to study brain tumors and their microenvironment	EDC03 Hereditary Syndromes	EDN03 Nurses & AHP PhD projects
13.15 - 14.00	LUNCH BREAK		
14.00 - 15.00	EDB04 Advanced complex preclinical models	EDC04 (incl. Nurses/AHPs track) Rehabilitation	
15.00 - 15.15	COFFEE BREAK		
15.15 - 16.30	EDB05 Non-invasive monitoring of brain tumor patients	EDC05 EANO Guidelines	EDN04 Patient- and public involvement in clinical practice development and in research
16.30 - 17.00	BREAK		
	EANO Meeting		
17.00 - 18.00	PD01 Health economics in neuro-oncology	PC01 Re-irradiation of gliomas and brain metastases	JS01 EANO-EANS Youngsters Second-line treatment in patients with recurrent glioblastoma

FRIDAY SEPTEMBER 16, EANO MEETING

	FESTSAAL Mezzanine	ZEREMONIENSAAL Mezzanine	FORUM Ground Floor	KÜNSTLER- ZIMMER Ground Floor
08.00 - 09.00	ME01 Shared decision making in neuro-oncology	ME02 Metabolic MR Imaging	ME03 Strategies for adoptive cell transfer	
09.00 - 09.15	TIME TO CHANGE ROOMS			
09.15 - 10.45	OS01 Liquid biomarkers for diagnosis/disease tracking in CNS tumours	JS02 EANO-EORTC Research and publication landscape	OS02 Symptom science and management	
10.45 - 11.15	COFFEE BREAK			
11.15 - 11.30	Opening and Presidential Address			
11.30 - 13.00	PL01 Artificial intelligence in Neuro-Oncology (and beyond)			
13.00 - 14.30	LUNCH BREAK			
13.15 - 14.15	CS01 Corporate Symposium	CS02 Corporate Symposium	WS01 How to survive the immunotherapy talks	WS02 Pitfalls in neurocognitive assessments
14.30 - 16.00	KS01 Recurrent glioblastoma	OS03 Clinically relevant vulnerabilities of CNS metastasis	OS04 Disparity for vulnerable patients: Does vulnerability in CNS tumors influence the management of patients?	
16.00 - 16.15	TIME TO CHANGE ROOMS			
16.15 - 17.45	KS02 Person-centred care and implementation	JS03 EANO-EAN Tumor predisposition syndromes	OS05 Dissecting and targeting pro-tumoral states of the micro-environment	
17.45 - 18.00	TIME TO CHANGE ROOMS			
18.00 - 19.45	18.00 - 19.30 Poster Viewing with authors (Gardehalle I & II, Ground Floor)		18.00 - 18.30 Poster Pitches	
			18.45 - 19.45 CS03 Corporate Symposium	

SATURDAY SEPTEMBER 17, EANO MEETING

	FESTSAAL Mezzanine	ZEREMONIENSAAL Mezzanine	FORUM Ground Floor	KÜNSTLER- ZIMMER Ground Floor
08.00 - 09.00	WU01 Modern clinical trial design	WU02 Exercise in rehabilitation of patients with brain tumors	WU03 Medulloblastoma	
09.00 - 09.15	TIME TO CHANGE ROOMS			
09.15 - 10.45	JS04 EANO-SNO Diffuse midline gliomas and other pediatric tumours	JS05 EANO-EANS Relevance of tumor-brain cross-talk from a surgical perspective	OS06 Quality of life	
10.45 - 11.15	COFFEE BREAK			
11.15 - 12.45	OS07 Highlights from clinical abstracts	OS08 Highlights from preclinical abstracts	OS09 Survivorship and late effects	
12.45 - 14.15	LUNCH BREAK			
13.00 - 14.00	WS03 EANO Youngsters Mentoring How to write a high impact paper	CS04 Corporate Symposium	CS05 Corporate Symposium	CS06 Corporate Symposium
14.15 - 15.45	OS10 Cellular and molecular mapping of glioblastoma	OS11 The leptomeninges in health and disease	OS12 EANO Youngsters Next generation low-grade glioma trials	
15.45 - 16.00	TIME TO CHANGE ROOMS			
16.00 - 17.00	PL02 Award Winning Abstracts	JS06 EANO-EURACAN EURACAN and rare brain cancers	JS07 EANO-EANM Innovative PET techniques	
17.00 - 18.30	17.00 - 18.30 Poster Viewing with authors (Gardehalle I & II, Ground Floor)		17.00 - 17.30 Poster Pitches	
			17.45 - 18.15 CS07 Corporate Symposium	

SUNDAY SEPTEMBER 18, EANO MEETING

	ZEREMONIENSAAL Mezzanine	FORUM Ground Floor
08.00 - 09.00	EANO General Assembly	
09.00 - 10.30	KS04 Management of Meningiomas	JS08 EANO-EACR Tumor Microenvironment Heterogeneity
10.30 - 11.00	COFFEE BREAK	
11.00 - 12.30	KS05 Treatment-induced plasticities	JS09 EANO-ESTRO Maximising the therapeutic benefits of radiotherapy for brain tumours
12.30 - 12.45	Closing Remarks	

PROGRAMME CHANGES

All contents are as per date of printing August 31, 2022

The up-to-date scientific programme is available in the online programme on the congress website and in the congress app.

The organiser reserves the right to modify the programme in case of external or unforeseen circumstances and cannot assume any liability. No refunds can be granted in case of cancellations of speakers, lack of space in the conference room or any other incidents during the congress which are beyond the control of the organiser.

LEGEND ABBREVIATIONS

ME	Meet the Experts
PL	Plenary Session
WU	Wake Up Session
OS	Oral Session
WS	Workshop
PC	Pro & Con Session
PD	Panel Discussion
JS	Joint Session
KS	Keynote Session



Full Programme

SIDE MEETINGS

All Side Meetings are closed meetings.
Information as per date of printing.

THURSDAY, SEPTEMBER 15

	<i>Meeting</i>	<i>Room</i>
16.00 - 18.30	Biomarker consortium	Radetzky App I

FRIDAY, SEPTEMBER 16

	<i>Meeting</i>	<i>Room</i>
08.00 - 09.30	EURACAN Meeting	Künstlerzimmer
10.45 - 11.30	EANO Youngsters Committee Meeting	Radetzky App I
11.45 - 12.45	EANO Nurse & Allied Health Professional Committee (NAC) Meeting	Radetzky App I
13.00 - 15.00	SANO Board Meeting	Radetzky App I
15.00 - 17.00	ÖGNP Meeting	Radetzky App I
18.00 - 19.00	EANO 2022 Meet the Industry Meeting	Hofburg Lounge

SATURDAY, SEPTEMBER 17

	<i>Meeting</i>	<i>Room</i>
13.00 - 14.00	EANO/SNO/OUP Meeting	Radetzky App I
13.00 - 14.00	EANO Mentorship Programme Get-together	Radetzky App II
17.00 - 18.00	National Societies Get-together	Hofburg Lounge

POSTER PRESENTATIONS

The posters have been divided into two separate poster viewing with authors sessions. Both poster numbers for both days will be shown on the poster board. The first poster number indicates the poster presented during the first poster session on Friday, the second poster number indicates the poster presented during the second poster session on Saturday.

To enable discussion and interaction with participants, it is mandatory for poster presenters or one of their group members to be present at the poster board during the according poster session.

SCHEDULE FOR DISPLAY, MOUNTING AND REMOVAL

Friday, September 16, 2022

Posters with poster numbers ending with "A" will be presented (e.g. P01.01.A).

Poster Viewing with authors I, 18.00 - 19.30 hrs

Poster mounting: as of 07.30 hrs

Poster removal: 19.30 - 20.00 hrs

Saturday, September 17, 2022

Posters with poster numbers ending with "B" will be presented (e.g. P01.02.B).

Poster Viewing with authors II, 17.00 - 18.30 hrs

Poster mounting: as of 07.30 hrs

Poster removal: 18.30 - 19.00 hrs

POSTER TOPICS

- | | |
|--|--|
| 01. Cognition in brain tumors | 10. Preclinical neuro-oncology |
| 02. Tumor heterogeneity, plasticity and impact on therapeutic response | 11. Clinical neuro-oncology |
| 03. Radiation technologies/Radiobiology/Radiotoxicity/Radiosensitizers | 12. Brain tumor microenvironment |
| 04. Pediatric brain tumors | 13. Artificial intelligence/Machine learning/Computation |
| 05. Multilayer diagnostics | 14. Liquid biomarkers |
| 06. Immunotherapy | 15. Development and validation of innovative imaging strategies (PET, metabolic MRI) |
| 07. Advanced Neurosurgical Techniques | 16. Leptomeningeal disease |
| 08. QoL/QoD | 17. Recurrent glioblastoma |
| 09. Symptom management | 18. Meningioma |

ABSTRACTS

Abstracts presented at the EANO 2022 are available on the congress app, the congress website and in the September digital issue of the journal "NeuroOncology".

EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY

EANO 2023 ROTTERDAM

De Doelen • Rotterdam, The Netherlands

*Save
the date*



www.eano.eu

SEPTEMBER 21 - 24, 2023
18TH MEETING & EDUCATIONAL DAY

OVERVIEW OF CORPORATE SYMPOSIA

FRIDAY, SEPTEMBER 16

		<i>Title</i>	<i>Company</i>	<i>Room</i>
13.15 - 14.15	CS01	TTFields future perspectives within and beyond neuro-oncology	Novocure	Festsaal
13.15 - 14.15	CS02	Plexiform neurofibromas (PNs) associated with NF1: Clinical cases and MDT approach in decision making	Alexion	Zeremoniensaal
18.45 - 19.45	CS03	Single cell and spatial transcriptomic methods to understand neuro-oncology	10x Genomics	Forum

SATURDAY, SEPTEMBER 17

		<i>Title</i>	<i>Company</i>	<i>Room</i>
13.00 - 14.00	CS04	PET Imaging for Primary Brain Tumours and CNS Metastases	Blue Earth Diagnostics Ltd	Zeremoniensaal
13.00 - 14.00	CS05	Overcoming the BBB using ultrasound – first in human and translational results	Carthera	Forum
13.00 - 14.00	CS06	ONC201 in H3 K27M Diffuse Mutant Glioma	Chimerix	Künstlerzimmer
17.45 - 18.15	CS07	Development and use of DNA methylation profiling for CNS Tumor classification	Illumina	Forum

SPONSORS

Gold Sponsor



Silver Sponsor



General Sponsors

10x Genomics

Blue Earth Diagnostics Ltd

Illumina

Servier

EXHIBITORS

10x Genomics

Blue Earth Diagnostics Ltd

medac

MSD

ZAP Surgical

European Association of Neuro-Oncology

International Brain Tumour Alliance

Alexion

Invenio Imaging

Medtronic

Novocure

ZEISS Medical Technology

Focused Ultrasound Foundation

GENERAL INFORMATION

Opening hours

Registration

HOFBURG FOYER, Ground Floor

Wednesday, September 14, 2022	16.00 - 19.00 hrs
Thursday, September 15, 2022	08.00 - 18.30 hrs
Friday, September 16, 2022	07.30 - 19.00 hrs
Saturday, September 17, 2022	07.30 - 18.00 hrs
Sunday, September 18, 2022	07.30 - 11.30 hrs

Preview Centre

ORCHESTERGANG, Mezzanine

Wednesday, September 14, 2022	16.00 - 19.00 hrs
Thursday, September 15, 2022	08.00 - 18.00 hrs
Friday, September 16, 2022	07.30 - 18.00 hrs
Saturday, September 17, 2022	07.30 - 17.00 hrs
Sunday, September 18, 2022	07.30 - 10.00 hrs

Exhibition

SEITENGALERIE & HOFBURG GALERIE, Mezzanine

Thursday, September 15, 2022	09.00 - 17.30 hrs
Friday, September 16, 2022	09.00 - 18.00 hrs
Saturday, September 17, 2022	09.00 - 17.00 hrs
Sunday, September 18, 2022	CLOSED

Poster Area

GARDEHALLE I & II, Ground Floor

Thursday, September 15, 2022	CLOSED
Friday, September 16, 2022	08.00 - 19.30 hrs
Saturday, September 17, 2022	08.00 - 18.30 hrs
Sunday, September 18, 2022	CLOSED

Cloakroom

GARTENSAAL, Ground Floor

Wednesday, September 14, 2022	16.00 - 19.00 hrs
Thursday, September 15, 2022	08.00 - 18.30 hrs
Friday, September 16, 2022	07.30 - 20.00 hrs
Saturday, September 17, 2022	07.30 - 18.45 hrs
Sunday, September 18, 2022	07.30 - 13.15 hrs

Location and Accessibility



Congress Venue

HOFBURG Vienna

Heldenplatz

1010 Vienna

www.hofburg.com

WIFI

Network: EANOmeeting

Password: eano2022

Public transport

For information about public transportation in Vienna, visit the website of the Wiener Linien: www.wienerlinien.at

Vienna

For information about Vienna, visit the congress website:

<https://www.eano.eu/eano2022/myconference/vienna/>

The European Association of Neuro-Oncology acknowledges and is grateful for the support of the Vienna Tourist Board:

MEETING
DESTINATION
VIENNA
NOW • TOGETHER

Congress Policy

Badges

Permission to the congress (scientific sessions, exhibition and poster area) is only permitted to registered participants. Therefore, wearing your badge throughout the entire congress is mandatory!

Language

The official language of the congress is English (no simultaneous translation available).

CME Credits

The 17th Meeting of the European Association of Neuro-Oncology, Vienna, Austria, 15/09/2022-18/09/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 24 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



To receive CME credits participants must scan their badge every day at the registration desk. After completion of the post-congress survey sent by email, participants will be able to download their personalised certificate of attendance (incl. CME credits) and/or have it sent to their email address. The certificate of attendance will indicate the number of CME credits that correspond with the badge scans.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities. Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Certificate of attendance

Confirmations of attendance and payment will be issued via email to all participants after the congress.

Catering

During the morning coffee breaks, refreshments (coffee, tea and snack) will be served free of charge to participants wearing name badges in the exhibition area.

During the lunch breaks, a warm meal as well as coffee and tea will be offered free of charge to participants wearing name badges in the exhibition area.

Additionally, participants will have the possibility to purchase refreshments (soft drinks, snacks, etc.) at the cash bar in the Hofburg Lounge.

Smoking Policy

The EANO 2022 is officially a “no-smoking-congress”. Note that smoking is banned in public buildings and private businesses (e.g. restaurants, shops, public transport, entertainment venues and workplaces).

Sustainability

The EANO is aiming at organising the congress in Vienna as a Green Meeting and is committed to environmental sustainability, a responsible use of resources and sustainable congress materials. The organiser therefore asks you to keep these aspects in mind, e.g. by using public transport to get to the venue and networking events and by using the existing possibilities for waste separation.



NICE TO MEET YOU!

Please note: Advance registration for all networking events is mandatory. Admission only with valid ticket. Limited attendance. Check ticket availability at the registration desk.

Networking Event

Location: Vienna City Hall - Festsaal
Date: Thursday, September 15, 2022
Start: 18.30 hrs



Address: Lichtenfelsgasse 2, 1010 Vienna
Public transport: Tramway 1, D, U2Z or 2;
Stations "Rathausplatz/Burgtheater" or "Rathaus"
Individual arrival.

Spend a nice evening with your colleagues while enjoying finger food and drinks.

Youngsters Networking Event

Location: Badeschiff Wien – Trinkhalle
Date: Friday, September 16, 2022
Start: 20.00 hrs



Address: Franz-Josefs-Kai 4 | Wolfgang-Schmitz-Promenade, 1010 Vienna
Public transport: U1 or U4 Station "Schwedenplatz" (Exit Urania) or
Tramway 1 or 2; Stations "Schwedenplatz" or "Julius-Raab-Platz"
Individual arrival.

Join the EANO Youngsters Networking Event and socialise with other young scientist. Snacks and 3 drinks are included in the price.

EANO Evening

Location: Heuriger Schübel-Auer
Date: Saturday, September 16, 2022
Start: 19.30 hrs



Address: Zahnradbahnstraße 17, 1190 Vienna
Public transport: Tramway D; Station "Nußdorf, Beethovengang"
Individual arrival.

Spend a wonderful evening with your colleagues and friends at a traditional Austrian restaurant. You will be able to enjoy traditional Austrian food and drinks together with live lounge music.


No sponsoring is used to fund any part of the evening.


FUTURE MEETINGS:

EANO 2023 - September 21-24, 2023 | De Doelen, Rotterdam
(NETHERLANDS)

EANO 2024 - October 17-20, 2024 | Scottish Event Campus (SEC),
Glasgow (UNITED KINGDOM)

GROUND FLOOR





PUT GBM **ON PAUSE...**



PUT LIFE **ON PLAY**



VISIT US AT EANO 2022

**15–18 SEPTEMBER 2022
NUMBER 8, HOFBURG GALERIE**

Newly diagnosed GBM: NovoTTF-200A (Optune) Treatment Kit is intended for the treatment of patients with newly diagnosed glioblastoma, after surgery and radiotherapy with adjuvant temozolomide, concomitant to maintenance temozolomide. The treatment is intended for adult patients, 18 years of age or older, and should be started more than 4 weeks after surgery and radiation therapy with adjuvant temozolomide. Treatment may be given together with maintenance temozolomide (according to the prescribing information in the temozolomide package insert) and after maintenance temozolomide is stopped.

For a complete overview of side effects, indications, contraindications, warnings and precautions, please refer to the product-specific User Manual (Europe):

https://www.optune.de/wp-content/uploads/2021/07/Optune_User_Manual_ver2.0.pdf

GBM, glioblastoma.

© 2022 Novocure GmbH. All rights reserved. Optune and Novocure are registered trademarks of Novocure GmbH.

EU-OPT-00370
August 2022

novocure®

 **OPTUNE®**
Elevate Expectations

EANO Meeting 2022, Vienna, Austria

Plexiform neurofibromas (PNs) associated with NF1: Clinical cases and MDT approach in decision making

Please join us for this Alexion sponsored medical symposium:

Friday 16th September, 2022 | 13:15–14:15 (CET) | Room: Zeremoniensaal



Professor Darren Hargrave,

Clinical Professor of
Paediatric Neuro-oncology (UCL
Great Ormond Street Institute of
Child Health, UK)



Professor Gareth Evans,

Consultant in Medical Genetics
and Cancer Epidemiology
(Central Manchester Hospitals
NHS Foundation Trust and The
Christie NHS Foundation Trust, UK)



Professor Amedeo Azizi,

Head of the Paediatric Neuro-
fibromatosis Program and
Paediatric Neuro-Oncology
Program (Medical University of
Vienna, Austria)



**Professor Juan Carlos
López Gutiérrez,**

Chief of the Paediatric Surgery
Service (Hospital Universitario
La Paz, Spain)

Start (CET)	Topic	Speaker
13:15–13:25	Introduction and overview of the NF1 PN patient pathway	Chair: Darren Hargrave (UK)
13:25–14:05	Clinical case discussion with the MDT	MDT speaker panel: Darren Hargrave (UK) Gareth Evans (UK) Amedeo Azizi (Austria) Juan Carlos López Gutiérrez (Spain)
14:05–14:15	Audience Q&A	Chair: Darren Hargrave (UK)

This is a non promotional industry symposium, funded and organised by Alexion
Please note, data relating to an Alexion product will be presented at this meeting. Product
registration conditions differ internationally, and prescribing information may vary depending on
approval in each country. This meeting is intended for healthcare professionals only

ALEXION
AstraZeneca Rare Disease

VEEVA ID: V2 M/INT/KOS-NF1/0041
Date of preparation: August 2022



Join the 10x Genomics Evening Symposium at EANO 2022

Friday, September 16

18:45 - 19:45 – Forum Room

Single Cell & Spatial Transcriptomic Methods to Understand Neuro-Oncology

- 10x Genomics introduction,
Matthias Schranzhofer, 10x Genomics
- Translational application of single cell and spatial sequencing in neuropathology,
Felix Sahm, Heidelberg University Hospital
- JAK STAT Inhibition reverses myeloid cell induced anti-tumor immunity in T cells,
Vidhya Madapusi Ravi, Medical Center - University of Freiburg
- Q&A

Meet us at the exhibition booth and visit 10xGenomics.com



BLUE EARTH

D I A G N O S T I C S

A Bracco Company

Blue Earth Diagnostics
cordially invites you to attend
a lunchtime symposium

PET Imaging for Primary Brain Tumours and CNS Metastases

Saturday, 17 September 2022 at 1pm
Zeremoniensaal Lecture Hall

**Role of PET radiopharmaceuticals in assessment of brain
tumours and treatment response evaluation – basics,
methods, advantages and limitations**

Dr Philipp Lohmann, PhD

Translational Researcher & Medical Physicist, Institute of Neuroscience and Medicine,
Medical Imaging Physics, Research Center Juelich (FZJ), Juelich, Germany

**The clinical relevance of PET radiopharmaceuticals in
neuro-oncology with focus on brain metastases**

Prof Norbert Galldiks, MD

Professor of Neurology, Senior Neurologist and Senior Neuro-Oncologist,
Dept. of Neurology of the University Hospital Cologne, Germany

**Amino Acid PET as a tool to differentiate recurrence vs
treatment-related effects**

Prof Samuel Chao, MD

Professor, CCLCM, Rose Ella Burkhardt Brain Tumour & Neuro-oncology Centre,
Dept. of Radiation Oncology, Cleveland Clinic, Ohio, USA

Panel discussion and Q&A

This scientific symposium is
fully funded and sponsored by
Blue Earth Diagnostics Ltd

JOIN US FOR A LUNCH SYMPOSIUM

Overcoming the BBB using ultrasound

FIRST IN HUMAN AND TRANSLATIONAL RESULTS

SEPTEMBER 17, 2022 - 13.00-14.00 - ROOM "FORUM" - PARTERRE LEVEL

13.00 • 13.10 **Drug delivery challenges for glioblastoma**

RICCARDO SOFFIETTI
MD, Science University Hospital,
Torino, Italy

13.10 • 13.20 **BBB Disruption Using Ultrasound:
From concept to FIH**

MICHAEL CANNEY
PhD, Carthera, Lyon, France

13.20 • 13.40 **Clinical Review of SonoCloud-9 Studies
for Glioblastoma and Intraoperative Drug
Measurements**

ADAM SONABEND
MD, Northwestern University,
Chicago, IL, USA

13.40 • 13.45 **Choice of Drugs and Perspectives**

ROGER STUPP
MD, Northwestern Medicine,
Chicago, IL, USA

13.45 • 14.00 **Take home messages and Q&A**

Moderators:
ALEXANDRE CARPENTIER
MD, APHP, Paris, France
ROGER STUPP
MD, Northwestern University,
Chicago, IL, USA

Over the past several decades, a wide variety of technologies have been explored to overcome the blood-brain barrier (BBB). Some of these have shown clinical benefit, but with technical limitations that have hampered their widespread adoption. The treatment of GBM is particularly affected by the inability of therapeutic compounds to reach infiltrated glioma cells at an effective concentration. BBB disruption using low-intensity pulsed ultrasound (LIPU) offers new hope in this field. SonoCloud, an implantable ultrasound device that overcomes the limitations of previous techniques, is currently being evaluated in clinical trials in Europe and the United States, with more than 450 treatments performed to date. An overview of nonclinical and clinical safety and efficacy data will be covered. This symposium will also be an opportunity to discuss new therapeutic perspectives opened by this technology.

CARTHERA 




ONC201 in H3 K27M-Mutant Diffuse Glioma

A European Association of Neuro-Oncology (EANO)
Annual Meeting (2022) Special Symposium

Saturday, 17 September
12:00-13:00

Künstlerzimmer Room
Mezzanine Level



ONC201, a first-in-class imipridone, has shown anti-cancer efficacy in patients with H3 K27M-mutant diffuse glioma.

JOIN US for a symposium discussing the development, recent findings, and future clinical evaluation of ONC201 in H3 K27M-mutant glioma in a Phase 3 trial.

Welcome & Introductory Remarks

- Allen Melemed, MD (Chimerix, Inc.)

12:00-12:05

ONC201: Mechanism of Action and Early Phase Development

- Joshua E. Allen, PhD (Chimerix, Inc.)

12:05-12:15

Clinical Efficacy and Safety in Diffuse Mutant Glioma

- Isabel Arrillaga-Romany, MD, PhD
(Massachusetts General Hospital)

12:15-12:30

ONC108, a Randomized Phase 3 Clinical Trial in Newly Diagnosed H3 K27M-mutant Diffuse Glioma

- Martin van den Bent, MD, PhD
(Brain Tumor Center at Erasmus MC Cancer Institute)


12:30-12:45

Panel Discussion and Q&A

- Panelists

12:45-13:00

illumina®



Illumina Symposium

“Development and use of DNA methylation profiling for CNS Tumor classification”

When

17th September 17:30

Where

Room name: Forum

Speaker

Prof. Dr. Dr. Felix Sahm, MBA

Managing Senior Physician, Head of Div. Molecular Neuropathology

Abt. Neuropathologie Pathologisches Institut

Universitätsklinikum Heidelberg & Klinische Kooperationseinheit Neuropathologie

Deutsches Krebsforschungszentrum (DKFZ)

Interested to find out more about Illumina's
Trusted bead-based microarray technology?

Visit illumina.com/science/technology/microarray.html
or scan the QR code.

